Carrieri P, Orefice G, La Pia S, Indaco A, D'Acunio F, Iadevaia V
Pharmatherapeutica. 1983;3(6):410-6.
A trial was carried out on 30 patients with cerebrovascular disease to evaluate the effect of indobufen, a new antiplatelet drug, on some platelet functions and coagulation, and its tolerance, after 12-months' treatment. From the results of the present study it appears that 2 hours after administration indobufen was able to reduce platelet aggregation induced by ADP, platelet adhesiveness, circulating platelet aggregates, and to increase bleeding time. These differences remained constant throughout the treatment period. Except in 3 patients, between the 8th and 12th months, who suffered an ischaemic attack with no aftermaths, no cerebrovascular ischaemic attacks occurred during indobufen treatment. No side-effects were observed. The data indicate that indobufen is a well-tolerated drug in all situations requiring antiplatelet treatment.
对30例脑血管疾病患者进行了一项试验，以评估新型抗血小板药物吲哚布芬在治疗12个月后对某些血小板功能和凝血的影响及其耐受性。从本研究结果来看，给药2小时后，吲哚布芬能够降低ADP诱导的血小板聚集、血小板黏附性、循环血小板聚集体，并延长出血时间。在整个治疗期间，这些差异保持不变。除了3例患者在第8至12个月期间发生了无后遗症的缺血性发作外，在吲哚布芬治疗期间未发生脑血管缺血性发作。未观察到副作用。数据表明，在所有需要抗血小板治疗的情况下，吲哚布芬都是一种耐受性良好的药物。
